M Toro-Montecinos1,2, F Ballescá1,2, C Ferrandiz1,2, A Teniente-Serra3, E Martinez-Caceres3, J M Carrascosa1,2. 1. a Department of Dermatology , Hospital Universitario Germans Trias i Pujol , Barcelona , Spain. 2. b Departamento de Medicina , Universidad Autònoma de Barcelona , Barcelona , Spain. 3. c Division of Immunology , Germans Trias i Pujol University Hospital and Health Sciences Research Institute , Badalona, Barcelona, Spain.
Abstract
BACKGROUND: Monitoring serum drug levels has been proposed as a useful tool for improving and personalizing the management of psoriasis. However, in the case of ustekinumab the usefulness of such monitoring was not demonstrated when drug levels were measured at week 12. OBJECTIVES: To evaluate the correlation of serum ustekinumab levels measured at weeks 6 and 12 with clinical response. METHODS: In a prospective cohort study, we enrolled patients with psoriasis treated with ustekinumab 45 mg every 12 weeks for at least 24 weeks. We measured serum ustekinumab levels at weeks 6 and 12 in each patient. Using the absolute PASI score, response to treatment was defined as optimal (≤1), excellent (≤3), appropriate (>3 and ≤5), or inappropriate (>5). RESULTS: About 54 serum samples from 27 patients were analyzed. No correlation was found between serum drug levels and absolute PASI at week 12. At week 6, an inverse linear correlation was found (p = .0001). Moreover, serum levels at week 6 were higher in patients with optimal, excellent and appropriate responses than in patients with an inappropriate response. CONCLUSIONS: Assessment of ustekinumab serum levels at week 6 could provide useful information in routine clinical practice.
BACKGROUND: Monitoring serum drug levels has been proposed as a useful tool for improving and personalizing the management of psoriasis. However, in the case of ustekinumab the usefulness of such monitoring was not demonstrated when drug levels were measured at week 12. OBJECTIVES: To evaluate the correlation of serum ustekinumab levels measured at weeks 6 and 12 with clinical response. METHODS: In a prospective cohort study, we enrolled patients with psoriasis treated with ustekinumab 45 mg every 12 weeks for at least 24 weeks. We measured serum ustekinumab levels at weeks 6 and 12 in each patient. Using the absolute PASI score, response to treatment was defined as optimal (≤1), excellent (≤3), appropriate (>3 and ≤5), or inappropriate (>5). RESULTS: About 54 serum samples from 27 patients were analyzed. No correlation was found between serum drug levels and absolute PASI at week 12. At week 6, an inverse linear correlation was found (p = .0001). Moreover, serum levels at week 6 were higher in patients with optimal, excellent and appropriate responses than in patients with an inappropriate response. CONCLUSIONS: Assessment of ustekinumab serum levels at week 6 could provide useful information in routine clinical practice.
Authors: Shan Pan; Teresa Tsakok; Nick Dand; Dagan O Lonsdale; Floris C Loeff; Karien Bloem; Annick de Vries; David Baudry; Michael Duckworth; Satveer Mahil; Angela Pushpa-Rajah; Alice Russell; Ali Alsharqi; Gabrielle Becher; Ruth Murphy; Shyamal Wahie; Andrew Wright; Christopher E M Griffiths; Nick J Reynolds; Jonathan Barker; Richard B Warren; A David Burden; Theo Rispens; Joseph F Standing; Catherine H Smith Journal: Clin Transl Sci Date: 2020-01-29 Impact factor: 4.689
Authors: N Van den Berghe; E De Keyser; R Soenen; L Meuleman; S Lanssens; A Gils; J Lambert Journal: Br J Dermatol Date: 2019-07-24 Impact factor: 9.302